- Home
- HRMY vs SPB Comparison
HRMY vs SPB Comparison
Compare HRMY & SPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | SPB |
|---|---|---|
| Founded | 2017 | 1906 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | HRMY | SPB |
|---|---|---|
| Price | $35.34 | $88.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $44.11 | ★ $82.40 |
| AVG Volume (30 Days) | ★ 910.7K | 309.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | 0.55 | ★ 2.16 |
| Revenue | $868,453,000.00 | ★ $3,802,100,000.00 |
| Revenue This Year | $19.75 | $2.03 |
| Revenue Next Year | $12.88 | $1.85 |
| P/E Ratio | $65.09 | ★ $40.48 |
| Revenue Growth | ★ 21.51 | 20.86 |
| 52 Week Low | $25.52 | $49.99 |
| 52 Week High | $40.87 | $90.60 |
Technical Indicators
Market Signals| Indicator | HRMY | SPB |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 58.58 |
| Support Level | $35.05 | $79.63 |
| Resistance Level | $35.47 | $90.60 |
| Average True Range (ATR) | 1.59 | 2.65 |
| MACD | -0.20 | 0.14 |
| Stochastic Oscillator | 46.08 | 76.50 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.